Skip to main content
. 2019 Sep 20;16(11):1412–1423. doi: 10.7150/ijms.34398

Figure 6.

Figure 6

Activation of MAPK signaling pathway by bortezomib. (A) Activation of ERK1/2, JNK and p38 MAPK in SNU-216 treated with TRAIL and/or bortezomib for 24 h and 48 h was analyzed by western blotting with antibodies against activation-associated phosphorylation of the kinases. (B) Cells were pretreated with U0126 (20 µM), SP600125 (20 µM) or SB203580 (20 µM) for 1 h followed by TRAIL and/or bortezomib treatment for 24 h and 48 h. Cell viability was measured by MTT assay and relative cell viability was calculated against untreated control. Results shown are the means ± SE of three independent experiments. P values were calculated from one-way ANOVA. (C) Expression of DR4 and DR5 in SNU-216 pretreated with U0126 (20 µM) or SP600125 (20 µM) for 1 h followed by TRAIL and/or bortezomib treatment for 24 h was visualized by western blot analysis. (D) Time-dependent expression of DR5, phospho-ERKs and ERKs in cells treated with bortezomib was examined by western blot analysis. All cells (A~D) were treated with TRAIL at 12.5 ng/ml and/or bortezomib (22.75 nM) for indicated time period. The data shown are representatives of triple experiments (A, C and D).